Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Prevalence rate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    218 result(s) found for: Prevalence rate. Displaying page 7 of 11.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next»
    EudraCT Number: 2021-003063-10 Sponsor Protocol Number: ARGX-113-2010 Start Date*: 2023-04-21
    Sponsor Name:argenx BV
    Full Title: An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
    Medical condition: Bullous Pemphigoid
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10006567 Bullous pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) GR (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned) ES (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001999-22 Sponsor Protocol Number: GO29834 Start Date*: 2016-02-25
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR DIFFUSE LARGE B...
    Medical condition: Relapsed or refractory, follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10012857 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory LLT
    18.1 100000004864 10012855 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) LLT
    18.1 100000004864 10012856 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-002467-42 Sponsor Protocol Number: BO29562 Start Date*: 2016-05-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A phase Ib/II study evaluating the safety and efficacy of Atezolizumab in combination with obinutuzumab plus lenalidomide in patients with relapsed or refractory follicular lymphoma
    Medical condition: Follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10016904 Follicle centre lymphoma, follicular grade I, II, III NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-002925-31 Sponsor Protocol Number: GO41717 Start Date*: 2020-05-18
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF TIRAGOLUMAB, AN ANTI-TIGIT ANTIBODY, IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH PLACEBO IN COMBINATION WITH ATEZOLIZUMAB IN ...
    Medical condition: Non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DK (Prematurely Ended) PL (Trial now transitioned) HU (Trial now transitioned) AT (Trial now transitioned) GR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-004362-17 Sponsor Protocol Number: MITO-16b/MANGO-OV2b/ENGOT-OV17 Start Date*: 2013-01-20
    Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE 'G. PASCALE'
    Full Title: A multicenter phase III randomized study with second line chemotherapy plus or minus bevacizumab in patients with platinum sensitive epithelial ovarian cancer recurrence after a bevacizumab/chemoth...
    Medical condition: platinum sensitive ovarian cancer patients progressing or recurring after a first-line treatment including bevacizumab.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) GR (Completed) FR (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-005108-89 Sponsor Protocol Number: VHIO17002 Start Date*: 2019-01-25
    Sponsor Name:Vall d’Hebron Institute of Oncology (VHIO)
    Full Title: Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumors.
    Medical condition: Subjects with advanced solid tumor
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004934-14 Sponsor Protocol Number: EMASPK01 Start Date*: 2014-01-15
    Sponsor Name:Institut klinické a experimentální medicíny
    Full Title: EVEROLIMUS VERSUS MYCOPHENOLIC ACID IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE DIFFERENCES IN RETINAL NEOVASCULARIZATION IN PATIENTS WITH DIABETIC RETINOPATHY
    Medical condition: simultaneous pancreas/kidney allograft transplantation
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004865 10048622 Pancreatic transplant LLT
    16.1 100000004865 10023438 Kidney transplant LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000367-83 Sponsor Protocol Number: ENGOT-Cx10/GEICO68-C/BEATcc Start Date*: 2018-08-08
    Sponsor Name:Grupo Español de Investigación en Cáncer de Ovario (GEICO)
    Full Title: A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persi...
    Medical condition: Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008342 Cervix carcinoma PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) NO (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001048-73 Sponsor Protocol Number: BAY41-6551/13084 Start Date*: 2013-07-25
    Sponsor Name:Bayer AG
    Full Title: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Pati...
    Medical condition: Gram-negative pneumonia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10035701 Pneumonia gram-negative bacterial NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-005743-14 Sponsor Protocol Number: 15.0214 Start Date*: 2016-04-15
    Sponsor Name:St Georges University Hospital NHS Foundation Trust
    Full Title: Fetal Atrial Flutter & Supraventricular Tachycardia (FAST) Therapy Trial
    Medical condition: Fetal atrial flutter without hydrops, supraventricular tachycardia without hydrops and supraventricular tachycardia with hydrops
    Disease:
    Population Age: In utero, Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-005668-21 Sponsor Protocol Number: NL0605 Start Date*: 2007-03-22
    Sponsor Name:Reckitt Benckiser Healthcare International Limited
    Full Title: A randomised, double-blind, parallel group, multiple-dose 3 month study of ibuprofen 400mg alone, paracetamol (acetaminophen) 1000mg alone, ibuprofen 200mg plus paracetamol 500mg and ibuprofen 400m...
    Medical condition: Pain.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10033371 Pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-002832-34 Sponsor Protocol Number: AZLI2016DN001 Start Date*: 2016-11-11
    Sponsor Name:Liverpool Heart & Chest Hospital
    Full Title: Aztreonam for inhalation for the treatment of acute exacerbations in cystic fibrosis. An open-label, randomised, cross-over pilot study of AZLI plus intravenous Colistin versus standard dual intrav...
    Medical condition: Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-019984-12 Sponsor Protocol Number: AMNCH-TCD-CHG-1-2010 Start Date*: 2010-07-21
    Sponsor Name:Adelaide & Meath Hospital, incorporating The National Children's Hospital
    Full Title: A multicentre randomised trial comparing the effects of 2% chlorhexidine gluconate in 70% isopropyl alcohol as a skin, exit site and catheter hub cleansing agent versus other forms of chlorhexidine...
    Medical condition: Prevention of central venous catheter-related infections in haemodialysis patients. This trial will evaluate the effectiveness of 2% chlorhexidine gluconate in 70%isopropyl alcohol as a skin, exit...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004651-36 Sponsor Protocol Number: GlibforCS Start Date*: 2021-05-21
    Sponsor Name:Academic Medical Center Amsterdam
    Full Title: Glibenclamide Treatment for Cantú syndrome
    Medical condition: Cantú syndrome
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000332-34 Sponsor Protocol Number: NL-07051985 Start Date*: 2017-08-23
    Sponsor Name:Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht
    Full Title: Topical or oral antibiotics for children with acute otitis media presenting with ear discharge?
    Medical condition: Acute otitis media with ear discharge
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10033080 Otitis media acute NOS LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-003659-52 Sponsor Protocol Number: PULSE Start Date*: 2018-04-02
    Sponsor Name:António Robalo Nunes
    Full Title: Impact of Iron Deficiency treatment with intravenous ferric carboxymaltose in patients with Chronic Obstructive Pulmonary Disease: an open-label, randomized, 2-arm, no treatment control, parallel s...
    Medical condition: Chronic Obstructive Pulmonary Disease and Iron Deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000349-14 Sponsor Protocol Number: CNIS793B12201 Start Date*: 2020-08-13
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase II, open label, randomized, parallel arm study of NIS793 (with and without spartalizumab) in combination with SOC chemotherapy gemcitabine/nab-paclitaxel, and gemcitabine/nab-paclitaxel alo...
    Medical condition: Pancreatic ductal adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) FR (Temporarily Halted) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) BE (Completed) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004033-20 Sponsor Protocol Number: ARGX-113-2005 Start Date*: 2021-09-08
    Sponsor Name:argenx BV
    Full Title: A Phase 3, Multicenter, Open-Label, Long-Term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
    Medical condition: Primary immune thrombocytopenia (ITP)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10005329 - Blood and lymphatic system disorders 10083843 Primary immune thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) IE (Prematurely Ended) DK (Completed) PT (Trial now transitioned) BG (Trial now transitioned) ES (Completed) GR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004511-31 Sponsor Protocol Number: cASPerCF_2007_OPBG_2019 Start Date*: Information not available in EudraCT
    Sponsor Name:Bambino Gesù Children's Hospital
    Full Title: Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection.
    Medical condition: Cystic Fibrosis and Aspergillus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10003488 Aspergillosis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Prematurely Ended) PT (Prematurely Ended) GR (Prematurely Ended) FR (Prematurely Ended) NL (Prematurely Ended) IE (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-003301-97 Sponsor Protocol Number: GO41767 Start Date*: 2020-04-15
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS CARBOPLATIN AND ETOPOSIDE WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE...
    Medical condition: Small cell lung cancer (SCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) AT (Completed) HU (Completed) BE (Completed) ES (Ongoing) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 23:04:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA